• 1086 Citations
  • 15 h-Index
1981 …2019
If you made any changes in Pure these will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 24 Similar Profiles
Hairy Cell Leukemia Medicine & Life Sciences
B-Cell Chronic Lymphocytic Leukemia Medicine & Life Sciences
Splenectomy Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Lymphoma, Large B-Cell, Diffuse Medicine & Life Sciences
B-Lymphocytes Medicine & Life Sciences
Natural Killer Cells Medicine & Life Sciences
B-Cell Lymphoma Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1981 2019

  • 1086 Citations
  • 15 h-Index
  • 104 Article
  • 4 Review article

Calreticulin mutation specific CAL2 immunohistochemistry accurately identifies rare calreticulin mutations in myeloproliferative neoplasms

Mózes, R., Gángó, A., Sulák, A., Vida, L., Reiniger, L., Timár, B., Krenács, T., Alizadeh, H., Masszi, T., Gaál-Weisinger, J., Demeter, J., Csomor, J., Matolcsy, A., Kajtár, B. & Bödör, C., Jan 1 2019, (Accepted/In press) In : Pathology.

Research output: Contribution to journalArticle

Calreticulin
Immunohistochemistry
Mutation
Neoplasms
Essential Thrombocythemia

Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program

Varga, G., Nagy, Z., Demeter, J., Kosztolányi, S., Szomor, Á., Alizadeh, H., Deák, B., Schneider, T., Plander, M., Szendrei, T., Váróczy, L., Illés, A., Bátai, Á., Pető, M. & Mikala, G., Jan 1 2019, In : Pathology and Oncology Research.

Research output: Contribution to journalArticle

Multiple Myeloma
Dexamethasone
Safety
Clinical Protocols
Disease-Free Survival
2 Citations (Scopus)

Efficacy and Tolerability of a 2-Year Rituximab Maintenance Therapy in Patients with Advanced Follicular Lymphoma after Induction of Response with Rituximab-Containing First Line-Regimens (HUSOM Study)

Schneider, T., Rosta, A., Losonczy, H., Radványi, G., Ujj, G., Egyed, M., Illés, A., Jakucs, J., Szerafin, L., Gasztonyi, Z., Masszi, T., Iványi, J., Demeter, J., Dombi, P., Tóth, A. & Borbényi, Z., Apr 1 2018, In : Pathology and Oncology Research. 24, 2, p. 199-205 7 p.

Research output: Contribution to journalArticle

Follicular Lymphoma
Disease-Free Survival
Therapeutics
Survival
Controlled Clinical Trials